Our Take
Grail has the enthusiasm of its own data but not yet the consensus of the field.
Why it matters
Multi-cancer early detection remains an unsolved clinical problem, and regulatory or guideline adoption is the only path to scale. ASCO's reticence signals that vendor enthusiasm alone won't move oncology practice.
Do this week
Oncology leaders: request the full ASCO presentation and independent peer review results before incorporating Galleri into institutional protocols.
Grail presents MCED data at ASCO
Grail, a liquid biopsy subsidiary of Illumina focused on multi-cancer early detection (MCED), presented study results for its Galleri test at the American Society of Clinical Oncology annual meeting. Company executives reported positive signals from the trial, according to reporting by MedTech Dive.
Grail framed the data as evidence that Galleri can detect cancer earlier than standard of care. The company has positioned the test as a potential screening tool for asymptomatic adults at risk of multiple cancer types.
ASCO's skepticism is the real story
ASCO's response to Grail's presentation was notably qualified. The society stated that more evidence is needed before Galleri should be incorporated into screening guidelines, according to the outlet. This is a material gap: guidelines adoption is the lever that drives clinical adoption and reimbursement at scale.
Vendor data presented at conferences has long been separated from independent validation in oncology. ASCO's public call for additional evidence suggests the field views Grail's results as a starting point, not a finishing line. Without guideline endorsement or third-party verification, hospital systems and insurers have limited incentive to integrate the test into standard workflows.
The gap between what Grail claims and what ASCO will endorse is where the real negotiation happens. MCED remains attractive in theory but unproven at scale in clinical practice.
What to watch
Monitor ASCO's 2024-2025 guideline updates for any formal recommendation on MCED screening. Until ASCO or comparable bodies issue a positive guideline, institutional adoption of Galleri will remain discretionary and likely slow. If you are evaluating MCED for your health system, request independent peer-reviewed data and clarify which payers will cover it before committing to integration work.